Candesartan effect on inflammation in hypertension

[1]  L. Dworkin,et al.  Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. , 2008, Kidney international.

[2]  J. Sowers,et al.  Insulin resistance and blood pressure , 2008, Current hypertension reports.

[3]  A. Hamsten,et al.  Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. , 2007, Atherosclerosis.

[4]  P. McBride,et al.  Triglycerides and risk for coronary heart disease. , 2007, JAMA.

[5]  B. Nordestgaard,et al.  Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. , 2007, JAMA.

[6]  A. Voors.  Vascular benefits of angiotensin receptor blockers , 2007, Expert opinion on investigational drugs.

[7]  H. C. V. van Zaanen,et al.  Postprandial inflammation and endothelial dysfuction. , 2007, Biochemical Society transactions.

[8]  Toshiko Tanaka,et al.  Peroxisome proliferator-activated receptor alpha polymorphisms and postprandial lipemia in healthy men. , 2007, Journal of lipid research.

[9]  K. Kario,et al.  The differential effects of angiotensin II type 1 receptor blockers on microalbuminuria in relation to low-grade inflammation in metabolic hypertensive patients. , 2007, American journal of hypertension.

[10]  Masayoshi Shichiri,et al.  Angiotensin II receptor type 1-mediated vascular oxidative stress and proinflammatory gene expression in aldosterone-induced hypertension: the possible role of local renin-angiotensin system. , 2007, Endocrinology.

[11]  L. Dworkin,et al.  Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. , 2007, Journal of the American Society of Nephrology : JASN.

[12]  C. Stefanadis,et al.  Beneficial Effects of Angiotensin II Type 1 Receptor Blocker Antihypertensive Treatment on Inflammation Indices: The Effect of Smoking , 2007, Journal of clinical hypertension.

[13]  Y. Nakajima,et al.  Relationship between insulin resistance and inflammatory markers and anti-inflammatory effect of losartan in patients with type 2 diabetes and hypertension. , 2006, Clinica chimica acta; international journal of clinical chemistry.

[14]  M. Martínez-Maldonado,et al.  Inflammation and the metabolic syndrome: Role of angiotensin II and oxidative stress , 2006, Current hypertension reports.

[15]  M. Quon,et al.  Anti-inflammatory and metabolic effects of candesartan in hypertensive patients. , 2006, International journal of cardiology.

[16]  A. Catapano,et al.  Lipoprotein remnants and endothelial dysfunction in the postprandial phase. , 2004, The Journal of clinical endocrinology and metabolism.

[17]  A. Witkowska,et al.  Soluble intercellular adhesion molecule-1 (sICAM-1): an overview. , 2004, European cytokine network.

[18]  W. Tsai,et al.  Effects of oxidative stress on endothelial function after a high-fat meal. , 2004, Clinical science.

[19]  E. Parks.  Recent findings in the study of postprandial lipemia , 2001, Current atherosclerosis reports.

[20]  M. Castro Cabezas,et al.  Postprandial Increase of Complement Component 3 in Normolipidemic Patients With Coronary Artery Disease: Effects of Expanded-Dose Simvastatin , 2001, Arteriosclerosis, thrombosis, and vascular biology.

[21]  M. Kinoshita,et al.  Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure. , 2000, Journal of the American College of Cardiology.

[22]  N Rifai,et al.  Clinical efficacy of an automated high-sensitivity C-reactive protein assay. , 1999, Clinical chemistry.

[23]  Z. Kornacewicz-Jach,et al.  Increased levels of factor VII, fibrinogen and activity of plasminogen activator inhibitor during postprandial triglyceridemia in patients with ischemic heart disease confirmed by angiography. , 1999, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[24]  A. Hamsten,et al.  Postprandial lipoproteins and progression of coronary atherosclerosis. , 1994, Atherosclerosis.

[25]  A. Hofman,et al.  Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[26]  D G Altman,et al.  Analysis of serial measurements in medical research. , 1990, BMJ.

[27]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[28]  L. Heding.  Determination of total serum insulin (IRI) in insulin-treated diabetic patients , 1972, Diabetologia.

[29]  R. Levy,et al.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. , 1972, Clinical chemistry.

[30]  Seymour Geisser,et al.  Statistical Principles in Experimental Design , 1963 .

[31]  R. Havel,et al.  The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum. , 1955, The Journal of clinical investigation.

[32]  W. Insull.  The pathology of atherosclerosis: plaque development and plaque responses to medical treatment. , 2009, The American journal of medicine.

[33]  Pd redaction.  Oświadczenie w sprawie konfliktu interesów , 2001 .

[34]  M. Blombäck,et al.  Activation of coagulation factor VII during alimentary lipemia. , 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

[35]  K. Borner,et al.  Enzymatische Bestimmung des Gesamtcholesterins mit dem Greiner Selective Analyzer (GSA-II) , 1977 .

[36]  A. Wahlefeld.  Triglycerides Determination after Enzymatic Hydrolysis , 1974 .